Trial
NCT02720120
A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA)
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Hoffmann-La Roche
Collaborators
—
Condition
Rheumatoid Arthritis
Intervention
Ocrelizumab
Why stopped
The overall benefit risk profile of ocrelizumab was not favorable in RA
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-03-28